Comparative Pharmacology
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE versus QDOLO.
MEPERIDINE HYDROCHLORIDE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia. It also has weak serotonergic activity.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
50-150 mg orally or intramuscularly every 3-4 hours as needed for pain. Maximum single dose: 150 mg. Maximum daily dose: 600 mg.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
3-4 hours in normal renal function; prolonged to >12 hours in hepatic impairment (cirrhosis) or renal failure (normeperidine accumulates)
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 70-80% as metabolites (normeperidine ~20%, meperidinic acid ~50%) and <5% unchanged; biliary/fecal: <10%
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist